Organization
Baylor Research Institute
8 clinical trials
Clinical trial
Quantitative Liver Function Tests Using CholatesStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Higher Neural and Cognitive Changes Following Anticholinergic Versus Beta 3 Agonist Versus Placebo Treatments in Female Patients With Overactive Bladder: a Multicenter Randomized Controlled Pilot TrialStatus: Completed, Estimated PCD: 2022-02-02
Clinical trial
Pilot Clinical Trial of Treatment With Bortezomib to Inhibit Homologous Recombination (HR) Followed by Pembrolizumab and Cisplatin in Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan CriteriaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Pilot Clinical Trial of Treatment With LY3023414 and Prexasertib to Inhibit Homologous Recombination (HR) in Patients With Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer (Amendment 1)Status: Completed, Estimated PCD: 2022-06-01
Clinical trial
Pilot Clinical Trial Examining the Safety and Efficacy of Neratinib in Combination With Ruxolitinib in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer With Chest Wall RecurrenceStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
Effects of a Progestin on Frequent and/or Prolonged Bleeding With Nexplanon™; a Randomized Double-Blinded Placebo-Controlled TrialStatus: Terminated, Estimated PCD: 2022-07-18
Clinical trial
MB001-067 A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO (COHORT A) AND A PROSPECTIVE, SINGLE GROUP, OPEN-LABEL, BLINDED OUTCOME TRIAL OF EXTENDED RELEASE EXENATIDE (COHORT B) IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS TRIAL) AMENDMENT 3Status: Completed, Estimated PCD: 2019-12-01